| Identification | More | [Name]
Irsogladine maleate | [CAS]
84504-69-8 | [Synonyms]
2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine maleate
2,4-diamino-6-(2,5-dichlorophenyl)-s-triazinemaleate
2,4-diamino-6-(2,5-dichlorophenyl)-s-triazinmaleate
3,5-triazine-2,4-diamine,6-(2,5-dichlorophenyl)-(z)-2-butenedioate(1:1)
gaslon
mn-1695
Irsogladin maleate
Gaslon N
Gasroil
Inomarl
Irgas | [Molecular Formula]
C13H11Cl2N5O4 | [MDL Number]
MFCD00873566 | [Molecular Weight]
372.16 | [MOL File]
84504-69-8.mol |
| Chemical Properties | Back Directory | [Melting point ]
181-182°C | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMF:30.0(Max Conc. mg/mL);80.61(Max Conc. mM)
DMSO:30.0(Max Conc. mg/mL);80.61(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.67(Max Conc. mM) | [Water Solubility ]
Insoluble in water | [form ]
White crystalline powder. | [color ]
White to Almost white | [Merck ]
5102 | [InChI]
InChI=1S/C9H7Cl2N5.C4H4O4/c10-4-1-2-6(11)5(3-4)7-14-8(12)16-9(13)15-7;5-3(6)1-2-4(7)8/h1-3H,(H4,12,13,14,15,16);1-2H,(H,5,6)(H,7,8)/b;2-1- | [InChIKey]
PJLVTVAIERNDEQ-BTJKTKAUSA-N | [SMILES]
N1=C(C2=CC(Cl)=CC=C2Cl)N=C(N)N=C1N.C(O)(=O)/C=C\C(O)=O | [CAS DataBase Reference]
84504-69-8(CAS DataBase Reference) |
| Safety Data | Back Directory | [WGK Germany ]
WGK 3 | [RTECS ]
XY5930000 | [HS Code ]
2933.69.6050 | [Storage Class]
11 - Combustible Solids | [Toxicity]
LD50 in male, female mice, rats (mg/kg): 6035, 5697, 3898, 2917 orally; 2841, 3216, 1600, 1524 s.c.; 775, 1006, 558, 545 i.p. (Ueda, 1984 p 474) |
| Hazard Information | Back Directory | [Description]
Irsogladine is a gastroprotective agent.1,2,3 It increases transfer of Lucifer yellow CH (Item No. 25573) between isolated rabbit gastric epithelial cells, indicating enhanced gap junction intercellular communication (GJIC).2 Irsogladine (3 mg/kg) inhibits gastric mucosal lesion formation and decreases in gastric mucosal blood flow induced by monochloramine in rats, effects that can be prevented by the nitric oxide synthase inhibitor L-NAME (Item No. 80210).1 It also inhibits superoxide anion production induced by fMLP (Item No. 21495) and increases cAMP levels in isolated human neutrophils in a concentration-dependent manner, similar to the phosphodiesterase 4 (PDE4) inhibitor rolipram (Item No. 10011132).3 | [Chemical Properties]
White Solid | [Uses]
An anti-ulcer drug. | [Uses]
antiulcerative;selective PDE4 inhibitor which also enhances gap junction intercellular communication | [Definition]
ChEBI: Irsogladine maleate is a dichlorobenzene. | [Biological Activity]
Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis. | [References]
[1] TAKASHI KYOI. Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.[J]. Journal of pharmacological sciences, 2003, 93 3: 314-320. DOI: 10.1254/jphs.93.314
[2] F UEDA T I K Ban. Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 274 2: 815-819.
[3] TAKASHI KYOI. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils[J]. Life sciences, 2004, 76 1: Pages 71-83. DOI: 10.1016/j.lfs.2004.06.016 |
|
|